期刊文献+
共找到225篇文章
< 1 2 12 >
每页显示 20 50 100
Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling 被引量:3
1
作者 Gang Chen Hong Qiu +3 位作者 Shan-Dong Ke Shao-Ming Hu Shi-Ying Yu Sheng-Quan Zou 《World Journal of Gastroenterology》 SCIE CAS 2013年第16期2481-2491,共11页
AIM: To investigate the molecular mechanisms underlying the reversal effect of emodin on platinum resistance in hepatocellular carcinoma. METHODS: After the addition of 10 μmol/L emodin to HepG2/oxaliplatin (OXA) cel... AIM: To investigate the molecular mechanisms underlying the reversal effect of emodin on platinum resistance in hepatocellular carcinoma. METHODS: After the addition of 10 μmol/L emodin to HepG2/oxaliplatin (OXA) cells, the inhibition rate (IR), 50% inhibitory concentration (IC 50 ) and reversal index (IC 50 in experimental group/IC 50 in control group) were calculated. For HepG2, HepG2/OXA, HepG2/OXA/T, each cell line was divided into a control group, OXA group, OXA + fibroblast growth factor 7 (FGF7) group and OXA + emodin group, and the final concentrations of FGF7, emodin and OXA in each group were 5 ng/mL, 10 μg/mL and 10 μmol/L, respectively. Single-cell gel electrophoresis was conducted to detect DNA damage, and the fibroblast growth factor receptor 2 (FGFR2), phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2) and excision repair cross-complementing gene 1 (ERCC1) protein expression levels in each group were examined by Western blotting. RESULTS: Compared with the IC50 of 120.78 μmol/L in HepG2/OXA cells, the IC 50 decreased to 39.65 μmol/L after treatment with 10 μmol/L emodin; thus, the reversal index was 3.05. Compared with the control group, the tail length and Olive tail length in the OXA group, OXA + FGF7 group and OXA + emodin group were significantly increased, and the differences were statistically significant (P < 0.01). The tail length and Olive tail length were lower in the OXA + FGF7 group than in the OXA group, and this difference was also statistically significant. Compared with the OXA + FGF7 group, the tail extent, the Olive tail moment and the percentage of tail DNA were significantly increased in the OXA + emodin group, and these differences were statistically significant (P < 0.01). In comparison with its parental cell line HepG2, the HepG2/OXA cells demonstrated significantly increased FGFR2, p-ERK1/2 and ERCC1 expression levels, whereas the expression of all three molecules was significantly inhibited in HepG2/ OXA/T cells, in which FGFR2 was silenced by FGFR2 shRNA. In the examined HepG2 cells, the FGFR2, p-ERK1/2 and ERCC1 expression levels demonstrated increasing trends in the OXA group and OXA + FGF7 group. Compared with the OXA group and OXA + FGF7 group, the FGFR2, p-ERK1/2, and ERCC1 expression levels were significantly lower in the OXA + emodin group, and these differences were statistically significant. In the HepG2/OXA/T cell line that was transfected with FGFR2 shRNA, the FGFR2, p-ERK1/2 and ERCC1 expression levels were significantly inhibited, but there were no significant differences in these expression levels among the OXA, OXA + FGF7 and OXA + emodin groups. CONCLUSION: Emodin markedly reversed OXA resistance by enhancing OXA DNA damage in HepG2/OXA cells, and the molecular mechanism was related to the inhibitory effect on ERCC1 expression being mediated by the FGFR2/ERK1/2 signaling pathway. 展开更多
关键词 HEPATOCELLULAR carcinoma EMODIN FIBROBLAST growth factor receptor 2 excision repair crosscomplementation group 1 Platinum resistance EXTRACELLULAR SIGNAL-REGULATED kinase
下载PDF
X-ray repair cross-complementing group 1 polymorphisms and hepatocellular carcinoma:A meta-analysis 被引量:4
2
作者 Tian Xie Zhen-Guang Wang +1 位作者 Jing-Lei Zhang Hui Liu 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第31期4207-4214,共8页
AIM: To perform a systematic meta-analysis to in- vestigate the association between X-ray repair crosscomplementing group 1 (XRCC1) polymorphisms and hepatocellular carcinoma (HCC) risk. METHODS: Relevant studie... AIM: To perform a systematic meta-analysis to in- vestigate the association between X-ray repair crosscomplementing group 1 (XRCC1) polymorphisms and hepatocellular carcinoma (HCC) risk. METHODS: Relevant studies extracted from PubMed, Embase, Wanfang, VIP and the Chinese National Knowledge Infrastructure databases up to March 2012 were included in the study. Stata software, version 11.0, was used for the statistical analysis. The odds ratios (ORs) and 95% confidence interval (CI) of the XRCC1 polymorphisms in HCC patients were analyzed and compared with healthy controls. The meta-analysis was performed using fixed-effect or random-effect methods, depending on the absence or presence of significant heterogeneity. RESULTS: Eleven studies with 2075 HCC cases and 2604 controls met our eligibility criteria (four studies, 888 cases and 938 controls for Arg194Trp, four studies, 858 cases and 880 controls for Arg280His, and nine studies, 1845 cases and 2401 controls for Arg399Gln). The meta-analysis revealed no associations between the Arg194Trp and Arg399GIn polymorphisms of the XRCC1 gene and HCC risk under all contrast models (codominant, dominant and recessive models) in the overall analysis and sensitivity analysis (the studies with controls not in the Hardy-Weinberg equilibrium were excluded). For XRCC1 Arg280His polymorphism, the overall analysis revealed the significant associa- tion between the His/His genotype and the increased risk of HCC (His/His vs Arg/Arg model, OR: 1.96, 95% CI: 1.03-3.75, P = 0.04). However, sensitivity analysis showed an altered pattern of result and non-significant association (OR: 2.06, 95% CI: 0.67-6.25, P = 0.20). The heterogeneity hypothesis test did not reveal any heterogeneity, and Begg's and Egger's tests did not find any obvious publication bias. CONCLUSION: The XRCC1 Arg194Trp and Arg399GIn polymorphisms are not associated with HCC risk. More rigorous association studies are needed to verify the involvement ofXRCC1 Arg280His polymorphism in HCC susceptibility. 展开更多
关键词 X-ray repair cross-complementing group 1 Polymorphism Hepatocellular carcinoma META-ANALYSIS
下载PDF
Tea polyphenols increase X-ray repair cross-complementing protein 1 and apurinic/apyrimidinic endonuclease/redox factor-1 expression in the hippocampus of rats during cerebral ischemia/reperfusion injury
3
作者 Zhi Wang Rongliang Xue +8 位作者 Xi Lei Jianrui Lv Gang Wu Wei Li Li Xue Xiaoming Lei Hongxia Zhao Hui Gao Xin Wei 《Neural Regeneration Research》 SCIE CAS CSCD 2012年第30期2355-2361,共7页
Recent studies have shown that tea polyphenols can cross the blood-brain barrier, inhibit apoptosis and play a neuroprotective role against cerebral ischemia. Furthermore, tea polyphenols can decrease DNA damage cause... Recent studies have shown that tea polyphenols can cross the blood-brain barrier, inhibit apoptosis and play a neuroprotective role against cerebral ischemia. Furthermore, tea polyphenols can decrease DNA damage caused by free radicals. We hypothesized that tea polyphenols repair DNA damage and inhibit neuronal apoptosis during global cerebral ischemia/reperfusion. To test this hypothesis, we employed a rat model of global cerebral ischemia/reperfusion. We demonstrated that intraperitoneal injection of tea polyphenols immediately after reperfusion significantly reduced apoptosis in the hippocampal CA1 region; this effect started 6 hours following reperfusion. Immunohistochemical staining showed that tea polyphenols could reverse the ischemia/reperfusion-induced reduction in the expression of DNA repair proteins, X-ray repair cross-complementing protein 1 and apudnic/apyrimidinic endonuclease/redox factor-1 starting at 2 hours. Both effects lasted at least 72 hours. These experimental findings suggest that tea polyphenols promote DNA damage repair and protect against apoptosis in the brain. 展开更多
关键词 global cerebral ischemia/reperfusion X-ray repair cross-complementing protein 1 apurinic/apyrimidinic endonuclease/redox factor-I tea polyphenols
下载PDF
ERCC1、K-ras、TP-73在替雷利珠单抗联合TP化疗方案治疗非小细胞肺癌中的评估价值
4
作者 王亚飞 张振军 +1 位作者 宋长亮 杨琼 《标记免疫分析与临床》 CAS 2024年第3期496-501,共6页
目的研究探讨核苷酸切除修复交叉互补基因1(ERCC1)、Kirsten-Rous肉瘤病毒蛋白(K-ras)、肿瘤蛋白P73(TP73)在替雷利珠单抗结合紫杉醇+顺铂(TP)化疗方案治疗NSCLC中的评估价值。方法选取2020年1月至2021年12月本院收治的126例NSCLC肺癌... 目的研究探讨核苷酸切除修复交叉互补基因1(ERCC1)、Kirsten-Rous肉瘤病毒蛋白(K-ras)、肿瘤蛋白P73(TP73)在替雷利珠单抗结合紫杉醇+顺铂(TP)化疗方案治疗NSCLC中的评估价值。方法选取2020年1月至2021年12月本院收治的126例NSCLC肺癌患者为研究对象,按随机抽签法分为对照组、观察组,各63例。对照组以TP化疗方案治疗,观察组增加替雷利珠单抗治疗。评估组间临床疗效、肿瘤标记蛋白、免疫指标、生存周期、不良反应。结果观察组患者的客观缓解率为69.84%(44/63)高于对照组患者为52.38%(33/63),观察组疾病控制率为82.54%(52/63),高于对照组患者为66.67%(42/63)(P<0.05)。化疗1周期、化疗3周期、化疗6周期时,观察组ERCC1、K-ras、TP-73水平均低于对照组(P<0.05)。治疗后观察组免疫功能补体C3、补体C4、CD40细胞低于对照组,NK细胞高于对照组(P<0.05)。观察组患者的TTP、PFS、总生存期均高于对照组(P<0.05)。观察组不良反应发生率为19.05%(12/63),对照组为12.70%(8/63),组间比较差异无统计学意义(P>0.05)。结论替雷利珠单抗联合TP化疗方案治疗肺癌有良好的治疗效果,能够改善患者免疫功能,延长患者生存周期,治疗安全性较好,且ERCC1、K-ras、TP-73水平变化可反映替雷利珠单抗联合TP化疗方案在肺癌治疗中的效果,在综合疗效评估中有较高的应用价值。 展开更多
关键词 替雷利珠单抗 紫杉醇 顺铂 核苷酸切除修复交叉互补基因1 基因Kirsten-Rous肉瘤病毒蛋白 肿瘤蛋白P73 非小细胞肺癌
下载PDF
吸烟对非小细胞肺癌患者ERCC1和RRM1表达的影响及与预后的相关性
5
作者 宋开放 刘谷一 孙江涛 《河南医学研究》 CAS 2024年第13期2347-2350,共4页
目的探讨吸烟对非小细胞肺癌(NSCLC)患者切除修复交叉互补基因1(ERCC1)和核糖核苷酸还原酶M1(RRM1)表达的影响及其与预后的关系。方法收集2015年8月至2018年8月河南科技大学第一附属医院收治的131例ⅢB期、Ⅳ期的NSCLC患者。依据有无吸... 目的探讨吸烟对非小细胞肺癌(NSCLC)患者切除修复交叉互补基因1(ERCC1)和核糖核苷酸还原酶M1(RRM1)表达的影响及其与预后的关系。方法收集2015年8月至2018年8月河南科技大学第一附属医院收治的131例ⅢB期、Ⅳ期的NSCLC患者。依据有无吸烟史将患者分为两组,其中非吸烟组64例,吸烟组67例,检测各组ERCC1和RRM1的表达水平,分析其与患者临床资料的相关性以及对患者预后的影响。结果吸烟组ERCC1高表达患者占比多于非吸烟组(P<0.05);两组ERCC1和RRM1的表达水平与患者性别、年龄、肿瘤大小、病理类型无关(P>0.05);吸烟指数≥400的患者ERCC1表达较高(P=0.018);两组ERCC1和RRM1低表达的患者化疗有效率均高于高表达患者(χ^(2)=6.194,P=0.013;χ^(2)=5.012,P=0.025);与吸烟组比较,非吸烟组化疗有效率高(P=0.045),1 a复发率低(P=0.001),无进展生存期(P=0.008)和总生存期长(P=0.005)。结论吸烟影响ERCC1的表达,且吸烟指数越高的患者ERCC1表达越高;而RRM1的表达与吸烟无关。吸烟患者化疗有效率、1 a复发率低于非吸烟患者,无进展生存期及生存期均短于非吸烟患者。 展开更多
关键词 非小细胞肺癌 切除修复交叉互补基因1 核糖核苷酸还原酶M1 吸烟 预后
下载PDF
ERCC1 mRNA和X线修复交叉互补组1基因多态性联合检测在局部晚期鼻咽癌患者放化疗中的应用价值
6
作者 吴梦馨 张丽娜 +1 位作者 何敏 谭金龙 《中国医刊》 CAS 2024年第1期86-89,共4页
目的 探讨核苷酸切除修复交叉互补组1(ERCC1)m RNA和X线修复交叉互补组1(XRCC1)基因多态性联合检测在局部晚期鼻咽癌患者放化疗中的应用价值。方法 选取2020年1月至2021年1月在江西省上饶市人民医院接受放化疗的41例局部晚期鼻咽癌患者... 目的 探讨核苷酸切除修复交叉互补组1(ERCC1)m RNA和X线修复交叉互补组1(XRCC1)基因多态性联合检测在局部晚期鼻咽癌患者放化疗中的应用价值。方法 选取2020年1月至2021年1月在江西省上饶市人民医院接受放化疗的41例局部晚期鼻咽癌患者,采用定量反转录聚合酶链反应检测外周血中ERCC1 mRNA的表达水平,采用限制性片段长度多态性聚合酶链反应检测XRCC1基因型(Arg194Trp、Arg280His、Arg399Gln),探讨ERCC1 mRNA和XRCC1多态性与局部晚期鼻咽癌患者放化疗效果、肿瘤复发及药物不良反应(ADR)的关系,并采用logistic回归分析局部晚期鼻咽癌患者ADR的影响因素。结果 完全缓解和部分缓解患者的ERCC1 mRNA及XRCC1多态性与疾病稳定和疾病进展患者比较差异无统计学意义(P>0.05)。肿瘤复发患者的ERCC1 mRNA及XRCC1多态性与非复发患者比较差异无统计学意义(P>0.05)。ADR患者XRCC1 Arg194Trp位点携带AG基因型、ERCC1 mRNA高表达的频率均高于非ADR患者,差异有统计学意义(P<0.05)。多因素logistic回归分析显示,XRCC1 Arg194Trp AG基因型(OR=1.876)、ERCC1mRNA高表达(OR=1.109)是局部晚期鼻咽癌患者放化疗期间发生ADR的影响因素(P<0.05)。结论 与单一检测相比,ERCC1 mRNA和XRCC1多态性联合检测预测局部晚期鼻咽癌患者放化疗期间ADR的价值更高,值得临床应用。 展开更多
关键词 核苷酸切除修复交叉互补组1 X线修复交叉互补组1基因多态性 联合检测 局部晚期鼻咽癌 放化疗
下载PDF
上皮性卵巢癌中ERCC1及转录因子Nanog蛋白的表达水平及意义
7
作者 刘慧玲 陈迎秀 +1 位作者 李靖 李大众 《中国妇幼健康研究》 2024年第8期32-37,共6页
目的探讨上皮性卵巢癌中核昔酸切除修复交叉互补组1(ERCC1)及转录因子Nanog蛋白的表达水平及意义。方法收集2019年1月至2022年12月在连云港市肿瘤医院妇科行卵巢手术切除的组织标本,其中上皮性卵巢癌组织标本101例(上皮性卵巢癌组),良... 目的探讨上皮性卵巢癌中核昔酸切除修复交叉互补组1(ERCC1)及转录因子Nanog蛋白的表达水平及意义。方法收集2019年1月至2022年12月在连云港市肿瘤医院妇科行卵巢手术切除的组织标本,其中上皮性卵巢癌组织标本101例(上皮性卵巢癌组),良性卵巢肿瘤组织标本80例(对照组),采用免疫组化检测ERCC1及Nanog蛋白表达水平,并分析与临床病理指标的关系。分别用0mg/L、1mg/L、2mg/L、4mg/L不同浓度的顺铂处理人卵巢癌OVCAR-3细胞24h,以Western blot检测细胞中ERCC1、Nanog蛋白的相对表达量,比较两组间ERCC1及Nanog蛋白的表达水平。结果上皮性卵巢癌组ERCC1、Nanog蛋白的阳性率均明显高于对照组,差异均有统计学意义(χ^(2)值分别为49.960、39.941,P<0.05)。Spearman相关性分析显示,上皮性卵巢癌组中ERCC1与Nanog蛋白表达水平呈正相关(r=0.463,P<0.01);对照组中ERCC1与Nanog蛋白表达水平无相关性(r=0.125,P>0.05)。在上皮性卵巢癌临床病理指标中,FIGO分期为Ⅲ+Ⅳ期的ERCC1、Nanog蛋白的阳性率均明显高于Ⅰ+Ⅱ期(χ^(2)值分别为9.578、9.756),淋巴结转移阳性的ERCC1、Nanog蛋白阳性率均明显高于淋巴结转移阴性(χ^(2)值分别为3.018、2.389),经比较差异均有统计学意义(P<0.05)。1mg/L、2mg/L、4mg/L浓度顺铂处理的ERCC1和Nanog蛋白相对表达量均明显高于0mg/L浓度顺铂处理的相对表达量,经比较差异均有统计学意义(F值分别为8.564、6.571,P<0.05);在ERCC1、Nanog蛋白相对表达量中,顺铂处理浓度1mg/L与0mg/L相比(t值分别为17.236、5.381)、顺铂处理浓度2mg/L与0mg/L相比(t值分别为5.621、6.380)、顺铂处理浓度4mg/L与0mg/L相比(t值分别为12.813、6.810),差异均有统计学意义(P<0.05);且随顺铂浓度的增加,ERCC1、Nanog蛋白相对表达量逐渐升高。结论ERCC1及Nanog蛋白在上皮性卵巢癌中呈现出高表达,可能与该病的发病机理和病情发展具有相关性。顺铂可诱导卵巢癌细胞ERCC1及Nanog蛋白高表达,可能为化疗耐药的潜在机制。 展开更多
关键词 上皮性卵巢癌 核昔酸切除修复交叉互补组1 Nanog蛋白 耐药性
下载PDF
Impact of SNP-SNP interactions of DNA repair gene ERCC5 and metabolic gene GSTP1 on gastric cancer/atrophic gastritis risk in a Chinese population 被引量:5
8
作者 Liang Sang Zhi Lv +2 位作者 Li-Ping Sun Qian Xu Yuan Yuan 《World Journal of Gastroenterology》 SCIE CAS 2018年第5期602-612,共11页
AIM To investigate the interactions of the DNA repair gene excision repair cross complementing group 5(ERCC5) and the metabolic gene glutathione S-transferase pi 1(GSTP1) and their effects on atrophic gastritis(AG) an... AIM To investigate the interactions of the DNA repair gene excision repair cross complementing group 5(ERCC5) and the metabolic gene glutathione S-transferase pi 1(GSTP1) and their effects on atrophic gastritis(AG) and gastric cancer(GC) risk.METHODS Seven ERCC5 single nucleotide polymorphisms(SNPs)(rs1047768, rs2094258, rs2228959, rs4150291, rs4150383, rs751402, and rs873601) and GSTP1 SNP rs1695 were detected using the Sequenom MassA RRAY platform in 450 GC patients, 634 AG cases, and 621 healthy control subjects in a Chinese population.RESULTS Two pairwise combinations(ERCC5 rs2094258 and rs873601 with GSTP1 rs1695) influenced AG risk(P_(interaction) = 0.008 and 0.043, respectively), and the ERCC5 rs2094258-GSTP1 rs1695 SNP pair demonstrated an antagonistic effect, while ERCC5 rs873601-GSTP1 rs1695 showed a synergistic effect on AG risk OR = 0.51 and 1.79, respectively). No pairwise combinations were observed in relation to GC risk. There were no cumulative effects among the pairwise interactions(ERCC5 rs2094258 and rs873601 with GSTP1 rs1695) on AG susceptibility(P_(trend) > 0.05). When the modification effect of Helicobacter pylori(H. pylori) infection was evaluated, the cumulative effect of one of the aforementioned pairwise interactions(ERCC5 rs873601-GSTP1 rs1695) was associated with an increased AG risk in the case of negative H. pylori status(P_(trend)= 0.043).CONCLUSION There is a multifarious interaction between the DNA repair gene ERCC5 SNPs(rs2094258 and rs873601) and the metabolic gene GSTP1 rs1695, which may form the basis for various inter-individual susceptibilities to AG. 展开更多
关键词 excision repair cross complementing group 5 Glutathione S-TRANSFERASE pi 1 ATROPHIC GASTRITIS Gastric cancer Single nucleotide polymorphisms
下载PDF
DNA repair gene XRCC1 polymorphisms and susceptibility to childhood acute lymphoblastic leukemia: a meta-analysis 被引量:4
9
作者 Juan Du Cong Lu +2 位作者 Guohui Cui Yan Chen Jing He 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第4期405-415,共11页
Objective: To estimate the relationship between genetic polymorphisms of X-ray repair cross- complementing group 1 (XRCC1) and the susceptibility to childhood acute lymphoblastic leukemia (ALL). Methods: Relevan... Objective: To estimate the relationship between genetic polymorphisms of X-ray repair cross- complementing group 1 (XRCC1) and the susceptibility to childhood acute lymphoblastic leukemia (ALL). Methods: Relevant case-control studies were enrolled in the meta-analysis. We applied Rev Man 4.2 software to pool raw data and test studies' heterogeneity and to calculate the incorporated odds ratio (OR) and 95% confidence interval (95% CI). Results: Our data showed that the OR for the Gln allele of the Arg399Gln polymorphism, compared with the Arg allele, was 1.35 (95% CI, 1.16-1.57; P〈0.0001) for childhood ALL patients. Similarly, the homozygous genotype Gln/Gln and heterozygous genotype Arg/Gln both significantly increased the risk of childhood ALL compared with the wild genotype Arg/Arg (OR =1.58; 95% CI, 1.13-2.21; P=0.008; OR =1.51; 95% CI, 1.21-1.87; P=0.0002). The dominant model of Arg399Gln was associated with childhood ALL risk (OR =1.54; 95% CI, 1.25-1.89; P〈0.0001). The ethnic subgroup analysis demonstrated that the Gln allele in all five ethnic groups was prone to be a risk factor for childhood ALL just with different degrees of correlation while Arg194Trp SNP showed a protective or risk factor or irrelevant thing in different races. Conclusions: XRCC1 399 polymorphism may increase the risk of childhood ALL. Different ethnic groups with some gene polymorphism have different disease risks. 展开更多
关键词 X-ray repair cross-complementing group 1 (XRCC1 gene polymorphism CHILDHOOD acute lymphoblastic leukemia (ALL)
下载PDF
Neuronal effects of SP600125 pretreatment in a rat model of cerebral ischemia/reperfusion injury Inhibited down-regulation of DNA repair protein 被引量:1
10
作者 Ning Wang Rongliang Xue +4 位作者 Fengzhen Yao Jiaxuan He Jianrui Lu Pengbo Zhang Gang Wu 《Neural Regeneration Research》 SCIE CAS CSCD 2009年第12期1055-1061,共7页
BACKGROUND: Recent studies have shown that the selective inhibitor of c-Jun N-terminal kinases (JNKs) signaling pathway, SP600125, exhibits neuronal protective effects in a rat model of brain ischemia/reperfusion. ... BACKGROUND: Recent studies have shown that the selective inhibitor of c-Jun N-terminal kinases (JNKs) signaling pathway, SP600125, exhibits neuronal protective effects in a rat model of brain ischemia/reperfusion. OBJECTIVE: To determine the mechanisms of neuroprotective effects of SP600125 in a rat model of brain ischemia/reperfusion, and determine the role of the JNK signaling pathway in SP600125-induced effects. DESIGN, TIME AND SETTING: A randomized, controlled, animal experiment was performed at the Animal Experiment Center, Medical School of Xi'an Jiaotong University from June 2007 to September 2008. MATERIALS: SP600125 was provided by Biosource, USA; rabbit anti-phospho-JNK (Thr183/Tyr185) polyclonal antibody from Cell Signaling Technology, USA; rabbit anti-X-ray repair cross-complementing protein 1 (XRCC1) and anti-Ku70 polyclonal antibodies from Santa Cruz Biotechnology, USA; and TUNEL kit from Beijing Huamei Biology, China. METHODS: A total of 108 male, 4-month-old, Sprague Dawley rats were randomly assigned to three groups, with 36 rats per group. The sham operation group and ischemia/reperfusion group (I/R group) were intracerebroventricularly injected with 10 μL 1% DMSO. The SP600125-treated group (pre-SP group) was given 10 μL SP600125 (3 μg/μL). Thirty minutes later, brain ischemia was induced in the I/R and pre-SP groups using the four-vessel occlusion method. Specifically, whole brain ischemia was induced for 6 minutes, and the clips were released to restore carotid artery blood flow. Rats from each group were observed at 2, 6, 12, 24, 48, and 72 hours, with 6 rats for each time point. The sham operation group was treated with the same surgical exposure procedures, with exception of occlusion of the carotid artery. MAIN OUTCOME MEASURES: Hematoxylin-eosin staining was used to observe neuronal survival in the hippocampal CA1 region, TUNEL was used to detect apoptosis in the hippocampal CA1 region, and immunohistochemistry was used to detect expression of phospho-JNK, XRCC1, and Ku70. RESULTS: Following brain ischemia/reperfusion, neuronal survival significantly decreased, and the number of apoptotic cells significantly increased (P 〈 0.01). Compared with the I/R group, neuronal survival significantly increased in the pre-SP group, and the number of apoptotic cells significantly decreased (P 〈 0.01). Expression of phospho-JNK increased, and XRCC1 and Ku70 significantly decreased (P 〈 0.05) following ischemia/reperfusion. Compared with the I/R group, expression of phospho-JNK decreased, and XRCC1 and Ku70 significantly increased in the pre-SP group (P 〈 0.05). Correlation analysis revealed an inverse correlation between phospho-JNK gray value and XRCC1 and Ku70 gray values in the hippocampal CA1 region (r = -0.983, -0.953, P 〈 0.01). CONCLUSION: SP600125 treatment decreased apoptosis induced by global brain ischemia/reperfusion in the rat hippocampal CA1 region. Results suggested that the neuroprotective effects were due to inhibited phosphorylation of JNK and reduced down-regulation of XRCC1 and Ku70. 展开更多
关键词 ischemia/reperfusion injury apoptosis c-Jun N-terminal kinases DNA repair protein X-ray repair cross-complementing protein 1 KU70
下载PDF
PMS2通过ERK/ERCC1通路对结肠癌SW480细胞生物学行为的影响
11
作者 黄雪茹 丁绪浩 +5 位作者 陈素贤 谭琦 吴月明 牛晓敏 王亚帝 佟青 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2023年第4期931-940,共10页
目的:探讨减数分裂后分离蛋白2(PMS2)表达对结肠癌SW480细胞生物学行为的影响,阐明PMS2与切除修复交叉互补组1(ERCC1)和细胞外调节蛋白激酶(ERK)信号转导通路的关系。方法:将PMS2 siRNA质粒和PMS2过表达质粒分别转染入结肠癌SW480细胞(... 目的:探讨减数分裂后分离蛋白2(PMS2)表达对结肠癌SW480细胞生物学行为的影响,阐明PMS2与切除修复交叉互补组1(ERCC1)和细胞外调节蛋白激酶(ERK)信号转导通路的关系。方法:将PMS2 siRNA质粒和PMS2过表达质粒分别转染入结肠癌SW480细胞(分别为PMS2敲减组和PMS2过表达组),同时设PMS2敲减对照组(siRNA-NC组)和PMS2过表达对照组(PMS2 control组)。采用实时荧光定量PCR(RT-qPCR)法检测各组细胞中PMS2 mRNA表达水平,Western blotting法检测各组细胞中PMS2蛋白表达水平,CCK-8法检测各组细胞增殖活性,细胞划痕实验检测各组细胞迁移率,Transwell小室实验检测各组细胞中侵袭细胞数,流式细胞术检测顺铂作用后各组细胞凋亡率。通过String数据库,对PMS2、ERCC1和ERK上下游蛋白的关系进行生物信息学分析。SW480细胞分别采用3条siRNA进行PMS2和ERCC1敲减,采用RT-qPCR法验证PMS2与ERCC1的相互作用,采用Western blotting法检测各组细胞中PMS2、细胞外调节蛋白激酶1/2(ERK1/2)和磷酸化ERK1/2(p-ERK1/2)蛋白表达水平。结果:RT-qPCR法和Western blotting法检测,PMS2基因敲减和过表达细胞模型构建成功。与siRNA-NC组比较,PMS2敲减组细胞增殖活性和细胞迁移率明显升高(P<0.05或P<0.01),侵袭细胞数明显增加(P<0.01),顺铂作用后细胞凋亡率明显降低(P<0.01);与PMS2 control组比较,PMS2过表达组细胞增殖活性和细胞迁移率明显降低(P<0.01),侵袭细胞数明显减少(P<0.01),顺铂作用后细胞凋亡率明显升高(P<0.01)。蛋白-蛋白互作(PPI)富集P值为2.09e-07,包含ERCC1和ERK1/2等相互作用节点数共有13个,提示PMS2、ERCC1和ERK1/2之间可能存在调控作用。与siRNA-NC组比较,各PMS2敲减组细胞中ERCC1 mRNA表达水平明显降低(P<0.05或P<0.01);与siERCC1-NC组比较,各ERCC1敲减组细胞中PMS2 mRNA表达水平差异无统计学意义(P>0.05)。与siRNA-NC组比较,PMS2敲减组细胞中PMS2、ERK1/2和p-ERK1/2蛋白表达水平均明显降低(P<0.05或P<0.01);与PMS2 control组比较,PMS2过表达组细胞中PMS2、ERK1/2和p-ERK1/2蛋白表达水平均明显升高(P<0.01)。结论:PMS2表达可影响结肠癌SW480细胞增殖、迁移、侵袭和抗凋亡能力。PMS2与ERCC1存在互相作用关系,并可通过调节ERCC1参与ERK信号转导通路。 展开更多
关键词 结肠肿瘤 SW480细胞 减数分裂后分离蛋白2 切除修复交叉互补组1 细胞外调节蛋白激酶1/2 信号通路
下载PDF
宫颈癌组织ERCC1、hMSH2表达及病理特征与铂类药物抵抗的相关性研究
12
作者 吴培培 施朕善 +2 位作者 李东鹏 马家芹 翟璠 《药学研究》 CAS 2023年第6期417-421,共5页
目的探究宫颈癌组织核苷酸切除修复交叉互补基因1(ERCC1)、错配修复基因2(hMSH2)表达与病理特征及铂类药物抵抗的相关性。方法收集2019年1月—2022年3月我院86例宫颈癌患者病理组织为观察组,另收集同期72例因子宫肌瘤手术切除的正常宫... 目的探究宫颈癌组织核苷酸切除修复交叉互补基因1(ERCC1)、错配修复基因2(hMSH2)表达与病理特征及铂类药物抵抗的相关性。方法收集2019年1月—2022年3月我院86例宫颈癌患者病理组织为观察组,另收集同期72例因子宫肌瘤手术切除的正常宫颈组织为对照组。比较2组核苷酸切除修复交叉互补基因1、错配修复基因2表达情况,分析癌组织核苷酸切除修复交叉互补基因1、错配修复基因2表达与病理特征相关性,铂类药物抵抗患者病理特征、核苷酸切除修复交叉互补基因1、错配修复基因2表达情况及铂类药物抵抗的多因素分析,分析核苷酸切除修复交叉互补基因1、错配修复基因2表达对铂类药物抵抗的预测价值。结果观察组核苷酸切除修复交叉互补基因1、错配修复基因2阳性率较对照组高(P<0.05);癌组织核苷酸切除修复交叉互补基因1、错配修复基因2表达与肌层浸润深度、分期、淋巴结转移有关(P<0.05);铂类药物抵抗患者与肌层浸润深度、分期、分化程度、淋巴结转移、核苷酸切除修复交叉互补基因1、错配修复基因2阳性有关(P<0.05);Logistic回归方程分析,结果显示,将肌层浸润深度、分期、分化程度、淋巴结转移控制后,癌组织核苷酸切除修复交叉互补基因1、错配修复基因2阳性仍为宫颈癌患者铂类药物抵抗的危险因素(P<0.05);ROC显示,核苷酸切除修复交叉互补基因1、错配修复基因2阳性联合预测铂类药物抵抗的AUC值最大,为0.702。结论宫颈癌组织核苷酸切除修复交叉互补基因1、错配修复基因2呈高表达状态,且与病理特征及铂类药物抵抗有关,二者可用于预测铂类药物反应性,从而指导临床治疗。 展开更多
关键词 宫颈癌 核苷酸切除修复交叉互补基因1 错配修复基因2 病理特征 铂类药物抵抗 相关性
下载PDF
鼻咽癌患者ERCC1表达水平及强度与其化疗效果及预后的关系探讨
13
作者 吴梦馨 张丽娜 何敏 《中国医学创新》 CAS 2023年第27期9-13,共5页
目的:探讨鼻咽癌(NPC)患者切除修复交叉互补基因1(ERCC1)表达水平及强度与其化疗效果及预后的关系。方法:以2018年1月-2020年6月经上饶市人民医院肿瘤科收治的NPC患者78例做回顾性研究,均接受2个周期诱导化疗后行同步放化疗,收集患者病... 目的:探讨鼻咽癌(NPC)患者切除修复交叉互补基因1(ERCC1)表达水平及强度与其化疗效果及预后的关系。方法:以2018年1月-2020年6月经上饶市人民医院肿瘤科收治的NPC患者78例做回顾性研究,均接受2个周期诱导化疗后行同步放化疗,收集患者病灶组织标本行免疫组化SP法测定ERCC1表达水平,分ERCC1阳性组及ERCC1阴性组,且ERCC1阳性组按强度予以亚组分组,分为弱阳性组、中度阳性组及强阳性组,比较ERCC1表达水平及强度与放化疗效果的关系,进行长期随访,采用Kaplan-Meier法(log-rank)绘制生存曲线分析ERCC1表达水平及强度与预后的关系。结果:两组性别、年龄、分期及美国东部肿瘤协作组(ECOG)评分比较,差异均无统计学意义(P>0.05);ERCC1阴性组客观缓解率(ORR)、疾病控制率(DCR)依次为67.86%、92.86%,与ERCC1阳性组ORR(36.00%)、DCR(70.00%)相比均更高,差异均有统计学意义(P<0.05);三组ORR、DCR比较,差异均无统计学意义(P>0.05);经Kaplan-Meier法绘制生存曲线显示:ERCC1阴性组3年生存率高于ERCC1阳性组(P<0.05)。结论:ERCC1表达阴性NPC患者化疗效果较佳,预后较好。 展开更多
关键词 鼻咽癌 切除修复交叉互补基因1 放化疗 强度
下载PDF
Ki-67、TEM1及ERCC1表达与胃癌新辅助化疗效果的相关性分析
14
作者 陈德志 陈巧辉 +4 位作者 林升禄 罗丽云 林冠 王佳坤 林光锬 《河北医药》 CAS 2023年第23期3550-3553,3558,共5页
目的分析Ki-67、TEM1及ERCC1表达与胃癌新辅助化疗效果的相关性。方法回顾性分析2018年1月至2022年12月就诊并行胃癌新辅助化疗的112例胃腺癌患者为研究对象,收集患者临床病历资料,采用免疫组化技术检测胃镜活检和手术病理中Ki-67、TEM1... 目的分析Ki-67、TEM1及ERCC1表达与胃癌新辅助化疗效果的相关性。方法回顾性分析2018年1月至2022年12月就诊并行胃癌新辅助化疗的112例胃腺癌患者为研究对象,收集患者临床病历资料,采用免疫组化技术检测胃镜活检和手术病理中Ki-67、TEM1及ERCC1的表达,分析与胃癌新辅助化疗效果相关的影响因素。结果胃癌新辅助化疗病理完全缓解16例(14.29%),有效68例(60.71%),无效44例(39.29%)。单因素分析:新辅助化疗有效率分别与T分期、临床分期、Ki-67表达、Ki-67变化、TEM1表达、ERCC1表达明显相关(P<0.05),病理完全缓解率分别与T分期、Ki-67表达、ERCC1表达明显相关(P<0.05)。多元Logistic回归分析:Ki-67表达、Ki-67变化、TEM1表达、ERCC1表达均是新辅助化疗有效的独立影响因素(P<0.05),Ki-67表达、ERCC1表达均是病理完全缓解的独立影响因素(P<0.05)。结论Ki-67、TEM1及ERCC1表达均是胃癌新辅助化疗效果的独立分子生物学预测因子,对胃癌新辅助化疗长期预后的判断具有一定的指导价值。 展开更多
关键词 胃癌 新辅助化疗 KI-67 TEM1 ERCC1
下载PDF
切除修复交叉互补基因1、乳腺癌易感基因1及微管蛋白β3检测在晚期肺鳞状细胞癌患者GP方案治疗中的指导意义
15
作者 李勇平 雷傲利 +1 位作者 李文革 李复红 《癌症进展》 2023年第21期2411-2414,共4页
目的 探讨切除修复交叉互补基因1(ERCC1)、乳腺癌易感基因1(BRCA1)及微管蛋白β3(TUBB3)检测在晚期肺鳞状细胞癌患者吉西他滨+顺铂(GP)方案治疗中的指导意义。方法 选取74例行GP方案治疗的晚期肺鳞状细胞癌患者,采用免疫组化法检测ERCC1... 目的 探讨切除修复交叉互补基因1(ERCC1)、乳腺癌易感基因1(BRCA1)及微管蛋白β3(TUBB3)检测在晚期肺鳞状细胞癌患者吉西他滨+顺铂(GP)方案治疗中的指导意义。方法 选取74例行GP方案治疗的晚期肺鳞状细胞癌患者,采用免疫组化法检测ERCC1、BRCA1及TUBB3表达情况。比较不同临床特征晚期肺鳞状细胞癌患者的ERCC1、BRCA1及TUBB3表达情况。根据免疫组化结果对患者进行分组,3阳性为A组(n=16),2阳性+1阴性为B组(n=18),1阳性+2阴性为C组(n=19),3阴性为D组(n=21),比较4组患者的临床特征、总有效率及疾病控制率。结果 74例晚期肺鳞状细胞癌患者肺鳞状细胞癌组织中ERCC1、BRCA1、TUBB3阳性表达率分别为45.95%、55.41%、47.30%。不同性别、临床分期、分化程度肺鳞状细胞癌患者肺鳞状细胞癌组织中ERCC1、BRCA1及TUBB3阳性表达率比较,差异均有统计学意义(P﹤0.05)。4组患者的性别、年龄、吸烟时间比较,差异均无统计学意义(P﹥0.05);4组患者的临床分期、分化程度比较,差异均有统计学意义(P﹤0.05)。4组患者的总有效率和疾病控制率比较,差异均有统计学意义(P﹤0.01),其中D组患者的总有效率和疾病控制率均最高,A组均最低。结论 ERCC1、BRCA1、TUBB3联合检测能够为GP方案治疗晚期肺鳞状细胞癌提供参考,有助于筛选有效治疗人群,提高GP方案治疗的有效性。 展开更多
关键词 切除修复交叉互补基因1 乳腺癌易感基因1 微管蛋白β3 晚期肺鳞状细胞癌 GP方案
下载PDF
ERCC1蛋白表达与局部晚期鼻咽癌同步放化疗疗效的关系 被引量:3
16
作者 梁嵘 李永强 +5 位作者 胡晓桦 刘志辉 廖小莉 林燕 原春玲 廖思娜 《临床肿瘤学杂志》 CAS 2014年第3期240-243,共4页
目的:探讨切除修复交叉互补基因1( ERCC1)在鼻咽癌组织中的表达,并分析其表达与局部晚期鼻咽癌同步放化疗疗效的关系。方法收集2010年1月至2010年12月经鼻咽部肿物活检确诊均为非分化型非角化性鼻咽癌患者76例,给予顺铂单药同步放... 目的:探讨切除修复交叉互补基因1( ERCC1)在鼻咽癌组织中的表达,并分析其表达与局部晚期鼻咽癌同步放化疗疗效的关系。方法收集2010年1月至2010年12月经鼻咽部肿物活检确诊均为非分化型非角化性鼻咽癌患者76例,给予顺铂单药同步放化疗。化疗方案具体为顺铂80mg/m2,静脉滴注,于放疗第1、22、43天进行;放疗采用常规分割照射,5次/周,鼻咽平均剂量74Gy(70~78Gy),同步放化疗结束后评价其近期疗效并随访远期生存情况。应用免疫组化法检测鼻咽癌组织中ERCC1蛋白表达,分析其表达与同步放化疗近期疗效及远期生存率的关系。结果76例鼻咽癌组织中ERCC1蛋白的阳性表达率为42.1%(32/76)。 ERCC1蛋白表达与鼻咽癌的T分期、临床分期有关(P<0.05),而与性别、年龄及N分期无关(P>0.05)。 ERCC1蛋白阳性表达者的有效率(RR)为75.0%(24/32),ERCC1阴性表达者的RR为97.7%(43/44),差异有统计学意义( P=0.008)。获得随访的72例患者的1年、2年、3年生存率分别为91.0%、83.3%、79.0%。 ERCC1阴性表达者的1年、2年、3年生存率分别为92.4%、87.8%、80.5%, ERCC1阳性表达者的1年、2年、3年生存率分别为87.9%、77.4%、77.4%,两者的中位生存期( OS)差异无统计学意义( P>0.05)。ERCC1阳性表达者中不同分级的中位OS差异有统计学意义( P<0.05)。结论 ERCC1蛋白的表达可能是预测局部晚期鼻咽癌同步放化疗近期疗效及预后的指标。 展开更多
关键词 鼻咽癌 DNA切除修复交叉互补基因1 同步放化疗 近期疗效 总生存期 excision repair cross-complementing gene 1( ERCC1)
下载PDF
晚期非小细胞肺癌组织中ERCC-1、Metallothionein、p53表达与铂类耐药性及预后的相关性分析 被引量:17
17
作者 黄培钰 梁小曼 +3 位作者 林素瑕 罗荣臻 侯景辉 张力 《癌症》 SCIE CAS CSCD 北大核心 2004年第7期845-850,共6页
背景与目的晚期非小细胞肺癌含顺铂方案化疗敏感性分子预测指标尚处于探索阶段。本研究分析晚期非小细胞肺癌石蜡包埋组织中错配切除修复蛋白(excisionrepaircrosscomplement-1,ERCC-1)、金属硫蛋白(metallothionein,MT)、p53蛋白与顺... 背景与目的晚期非小细胞肺癌含顺铂方案化疗敏感性分子预测指标尚处于探索阶段。本研究分析晚期非小细胞肺癌石蜡包埋组织中错配切除修复蛋白(excisionrepaircrosscomplement-1,ERCC-1)、金属硫蛋白(metallothionein,MT)、p53蛋白与顺铂化疗敏感性的关系,并观察这些指标与病人生存的关系。方法收集1994年1月-2001年12月在本院经病理组织学诊断的用含铂方案(Gemzar+DDP或NVB+DDP)化疗的初治晚期非小细胞肺癌患者的病理标本,采用免疫组化方法检测ERCC-1、MT、p53的表达,并将病人的疗效和生存资料与上述指标的表达进行比较。样本率的比较用χ2检验,用Kaplan-meier法和Cox回归进行生存分析。结果本组51例标本中,ERCC-1阳性率为42.8%,MT阳性率为57.5%,p53阳性率为37.8%。化疗有效率在ERCC-1、MT、p53阴性组和阳性组分别为33.3%、35.3%、21.4%和16.7%、27.3%、35.3%(即分别为1.99倍,1.29倍,0.61倍),但均未达统计学差异(P>0.05),ERCC-1,MT均阴性组有效率为37.5%,均阳性组有效率为14.3%,前者为后者的2.6倍,但未达统计学差异(P>0.05)。平均生存期ERCC-1、MT、p53蛋白阴性组和阳性组分别为621.03天/523.14天,556天/479天,599.64天/416.60天。Kaplan-meier分析显示三者过度表达均提示预后不良,但Cox回归分析显示只? 展开更多
关键词 非小细胞性肺癌 ERCC-1 MT p53 顺铂 耐药 预后
下载PDF
ERCC1在鼻咽癌组织中的表达及其与顺铂化疗敏感性的关系 被引量:11
18
作者 曹轶林 邱小芬 +3 位作者 刘陶文 徐李容 屈元姣 陈熙 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2009年第3期292-295,共4页
目的:探讨核苷酸切除修复交叉互补基因1(excision repair cross-complementing 1,ERCC1)在鼻咽癌(nasopharyn-geal carcinoma,NPC)组织中的表达及其与顺铂化疗敏感性的关系。方法:选取广西南溪山医院2006年6月至2008年6月确诊的82例中晚... 目的:探讨核苷酸切除修复交叉互补基因1(excision repair cross-complementing 1,ERCC1)在鼻咽癌(nasopharyn-geal carcinoma,NPC)组织中的表达及其与顺铂化疗敏感性的关系。方法:选取广西南溪山医院2006年6月至2008年6月确诊的82例中晚期NPC患者,接受顺铂+5-FU的基础化疗加放疗,应用免疫组化法检测NPC癌组织中ERCC1蛋白的表达及其中的34例患者癌旁上皮组织(对照组)中ERCC1蛋白的表达。结果:NPC癌旁上皮组织中ERCC1的阳性率为88.2%,显著高于NPC癌组织中ERCC1的阳性率63.4%(P<0.05)。ERCC1表达与NPC患者年龄有关(P<0.05),而与性别、T分期、N分期、M分期无关(P>0.05)。ERCC1蛋白表达阳性的NPC患者化疗有效率为36.5%,ERCC1阴性患者化疗有效率为63.3%,两者差异有统计学意义(P<0.05)。结论:ERCC1在中晚期NPC癌组织中低表达,ERCC1表达与顺铂+5-FU方案的疗效呈负相关,检测ERCC1表达有助于预测NPC患者对顺铂化疗的敏感性。 展开更多
关键词 鼻咽癌 核苷酸切除修复交叉互补基因1(ERCC1) 顺铂 免疫组织化学染色
下载PDF
18F-fluorodeoxyglucose Uptake with Expression of Excision Repair Cross-complementary Group I and Ribonucleotide Reductase Subunit M1 in Non-small Cell Lung Cancer
19
作者 Na Hu Yun-Hua Wang +2 位作者 Dai-Qiang Li Xiao-Huang Yang Yan-Lin Tan 《Chinese Medical Journal》 SCIE CAS CSCD 2017年第17期2117-2118,共2页
Fluorodeoxyglucose positron emission tomography/conlputed tomography (FDG PET/CT) is widely applied in non-small cell lung cancer (NSCLC). The standardized uptake value (SUV), a semi-quantitative index, plays an... Fluorodeoxyglucose positron emission tomography/conlputed tomography (FDG PET/CT) is widely applied in non-small cell lung cancer (NSCLC). The standardized uptake value (SUV), a semi-quantitative index, plays an essential role in NSCLC tbr diagnosis, staging, and efficacy evaklation. It has been px3posed that the SUV of tumors may correlate with the presence or absence of chemotherapy resistance-associated biomarkers based on studies that have displayed a close correlation between SUV and the expression levels of excision repair cross-complementary Group 1 (ERCC 1 )1~1 and Tp53-induced glycolysis and apoptosis regulator.121 FDG avidity of NSCLC and ERCC 1 and ribonucleotide reductase subunit M 1 (RRM 1 ) levels have not been as extensively investigated. Based on these findings, we looked tbr correlations among metabolic parameters (SUVm,,. metabolic tumor volume [MTV], and total lesion glycolysis [TLG]) and ERCC1 and RRM1 expression in patients with NSCLC, to investigate whether FDG uptake reflects the presence or absence ofchemoresistance proteins (ERCC1 and RRM 1 ) within tumor cells. 展开更多
关键词 Computed Tomography: excision repair cross-complementary Group 1 Non-small Cell Lung Cancer: Positron-emission Tomography Ribonucleotide Reductase Subunit M 1
原文传递
食管癌组织中ERCC1和GSTP1表达量与铂类化疗药物敏感性及凋亡、增殖基因表达量的相关性 被引量:9
20
作者 丁晓权 毕鑑红 +4 位作者 马志刚 蒋占鑫 席俊峰 刘鹏 张志斌 《海南医学院学报》 CAS 2017年第6期809-812,共4页
目的:研究食管癌组织中ERCC1和GSTP1表达量与铂类化疗药物敏感性及凋亡、增殖基因表达量的相关性。方法:选择在我院接受PF方案化疗的晚期食管癌患者,化疗前收集食管癌组织并根据化疗后的效果分为化疗敏感组和化疗耐药组,检测食管癌组织... 目的:研究食管癌组织中ERCC1和GSTP1表达量与铂类化疗药物敏感性及凋亡、增殖基因表达量的相关性。方法:选择在我院接受PF方案化疗的晚期食管癌患者,化疗前收集食管癌组织并根据化疗后的效果分为化疗敏感组和化疗耐药组,检测食管癌组织中ERCC1、GSTP1以及凋亡基因、增殖基因的表达量。结果:化疗敏感组食管癌组织中ERCC1、GSTP1的蛋白含量以及蛋白阳性表达率均显著低于化疗耐药组,MBP1、DEC1、PTEN的蛋白含量显著高于化疗耐药组,PLCE1、CyclinD1、PAR2的蛋白含量显著低于化疗耐药组;ERCC1、GSTP1阳性表达食管癌组织中MBP1、DEC1、PTEN的蛋白含量显著低于ERCC1、GSTP1阴性表达食管癌组织,PLCE1、CyclinD1、PAR2的蛋白含量显著高于ERCC1、GSTP1阴性表达食管癌组织。结论:食管癌组织中高表达的ERCC1和GSTP1能够降低癌细胞对铂类化疗药物的敏感性,在铂类药物化疗过程中抑制细胞凋亡、促进细胞增殖。 展开更多
关键词 食管癌 切除修复交叉互补基因1 凋亡 增殖
下载PDF
上一页 1 2 12 下一页 到第
使用帮助 返回顶部